Multicellular factor inhibitor BNZ-1 treats skin T-cell lymphoma: safe and effective.

Biopharmaceuticals today announced that phase clinical trials have shown good safety and efficacy in treating patients with refracted skin cell lymphoma () for, and polycytokine inhibitorsThis phase of clinical research is designed to assess the safety and efficacy of single drug therapy in patients with standard care and treatment failuresThe study recruited a total of patientsThe primary endpoint is the overall safety after treatmentAfter the trial, the researchers extended the treatment for a period of several months to further assess safety and clinical responseOverall, there is good tolerance without dose-limiting toxicity
The clinical symptoms of patients in the dose group improved significantlyThe results were as follows: more than % of the subjects improved the tumor burden without any accompanying therapy; about half of the patients received partial remission in the score (at least lower than the baseline), % of the subjects received full remission, and the average duration of remission was days (months) for those who achieved partial or complete remission at the time of the data cut-off in this mid-term analysis